- Home
- CMAX vs ONVO Comparison
CMAX vs ONVO Comparison
Compare CMAX & ONVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CMAX
- ONVO
- Stock Information
- Founded
- CMAX 2011
- ONVO 2007
- Country
- CMAX United States
- ONVO United States
- Employees
- CMAX N/A
- ONVO N/A
- Industry
- CMAX Computer Software: Prepackaged Software
- ONVO Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CMAX Technology
- ONVO Health Care
- Exchange
- CMAX Nasdaq
- ONVO Nasdaq
- Market Cap
- CMAX 7.2M
- ONVO 7.2M
- IPO Year
- CMAX N/A
- ONVO N/A
- Fundamental
- Price
- CMAX $1.69
- ONVO $0.42
- Analyst Decision
- CMAX Hold
- ONVO
- Analyst Count
- CMAX 1
- ONVO 0
- Target Price
- CMAX $6.40
- ONVO N/A
- AVG Volume (30 Days)
- CMAX 787.8K
- ONVO 97.0K
- Earning Date
- CMAX 11-26-2024
- ONVO 11-26-2024
- Dividend Yield
- CMAX N/A
- ONVO N/A
- EPS Growth
- CMAX N/A
- ONVO N/A
- EPS
- CMAX N/A
- ONVO N/A
- Revenue
- CMAX $784,551,000.00
- ONVO $103,000.00
- Revenue This Year
- CMAX $13.01
- ONVO $59.08
- Revenue Next Year
- CMAX $32.42
- ONVO $18.24
- P/E Ratio
- CMAX N/A
- ONVO N/A
- Revenue Growth
- CMAX 9.06
- ONVO N/A
- 52 Week Low
- CMAX $1.18
- ONVO $0.32
- 52 Week High
- CMAX $30.00
- ONVO $1.74
- Technical
- Relative Strength Index (RSI)
- CMAX 43.35
- ONVO 47.62
- Support Level
- CMAX $1.63
- ONVO $0.39
- Resistance Level
- CMAX $1.81
- ONVO $0.46
- Average True Range (ATR)
- CMAX 0.31
- ONVO 0.05
- MACD
- CMAX -0.02
- ONVO -0.00
- Stochastic Oscillator
- CMAX 21.93
- ONVO 62.27
About CMAX CareMax Inc.
CareMax Inc is a technology-enabled care platform providing value-based care and chronic disease management to seniors. It operates various owned medical centers that offer a comprehensive suite of healthcare and social services and a proprietary software and services platform that provides data, analytics, and rules-based decision tools/workflows for physicians across the United States.
About ONVO Organovo Holdings Inc.
Organovo Holdings Inc is a biotechnology company focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis (UC), based on demonstration of clinical promise in three-dimensional (3D) human tissues as well as preclinical data. FXR is a mediator of gastrointestinal and liver diseases.